An investigation on behalf of investors in Stemline Therapeutics Inc (NASDAQ:STML) shares over potential wrongdoing at Stemline Therapeutics Inc was announced and NASDAQ:STML stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 05/11/2018 -- An investigation on behalf of current long-term investors in shares of Stemline Therapeutics Inc (NASDAQ:STML) was announced over potential breaches of fiduciary duties by certain officers and directors at Stemline Therapeutics Inc.
Investors who purchased shares of Stemline Therapeutics Inc (NASDAQ:STML) and currently hold any of those NASDAQ:STML shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Stemline Therapeutics Inc (NASDAQ:STML officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
On February 3, 2017, a lawsuit was filed against Stemline Therapeutics Inc (NASDAQ:STML) over alleged securities laws violations. The plaintiff claimed that the Defendants made false and/or misleading statements and/or failed to disclose that a cancer patient in a Stemline Therapeutics Inc clinical trial tied to SL-401 died from a severe side effect on January 18, 2017, and that as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased shares of Stemline Therapeutics Inc (NASDAQ:STML) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels